Health — 31 July 2013

bigstock-The-words-medical-marijuana-su-17121803By Richard Lenti

The use of a synthetic marijuana derivative in treating multiple sclerosis (MS) is being questioned after the first major non-commercial study of its main active ingredient, tetrahydrocannabinol (THC), found the drug had little effect in slowing the course of the disease.

Researchers in England enrolled nearly 500 patients over an eight year span. People with progressive MS received either THC capsules or a placebo for three years to see how their MS changed over this period.

Overall, the study found no evidence to support the effectiveness of THC on MS progression, using either a disability scale administered by neurologists or a patient reported scale measuring the drug’s impact.

There was some evidence to suggest a beneficial effect in patients at the lower end of the disability scale, but the benefit was only found in a small group of people rather than the whole population.

Read more at National Pain Report.


About Author

Richard Lenti

Richard Lenti has worked as a news writer for the last 20 years at various television stations in Los Angeles. He is a Golden Mike winner and a graduate of California State University, Fresno. With roots in print journalism, Richard is excited to be “published” once again; having people read his work as opposed to having it read to them. As a freelance writer his work has appeared in the Easy Reader, L.A. Jazz Scene, Irrigation and Green Industry, and the KCAL 9 Online website.

(0) Readers Comments

Comments are closed.